Waxman/Hatch patent reform
Sen. Hatch (R-Utah) has asked representatives from the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and the Generic Pharmaceutical Industry Association to meet with him Nov. 17 to discuss potential revisions to the Waxman/Hatch patent reform legislation of 1984
You may also be interested in...
BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011